Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer

Liao,Yunfei; Gu,Jie; Wu,Yongbing; Long,Xiang; Ge,Di; Xu,Jianjun; Ding,Jianyong

doi:10.3892/ol.2016.4474

Low level of 5-Hydroxymethylcytosine predicts poor prognosis in non-small cell lung cancer

Authors:
- Yunfei Liao
- Jie Gu
- Yongbing Wu
- Xiang Long
- Di Ge
- Jianjun Xu
- Jianyong Ding
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Thoracic Surgery, The Affiliated Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China
Published online on: April 19, 2016 https://doi.org/10.3892/ol.2016.4474
Pages: 3753-3760

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The loss of 5-hydroxymethylcytosine (5-hmC) has previously been demonstrated to be implicated in the initiation and progression of various tumors. However, its role in non‑small cell lung cancer (NSCLC) remains unknown. The present study aimed to determine the level of 5‑hmC in NSCLC and their adjacent normal lung tissues by immunohistochemistry and dot‑blot analysis; then the relationship between 5‑hmC level and the clinicopathological features of NSCLC and the prognostic significance of 5‑hmC level in NSCLC patients were analyzed. By employing the dot‑blot analysis, a significant reduction of 5‑hmC level in NSCLC tissues compared with the adjacent normal tissues was detected, which were further verified by the immunohistochemistry results on tissue microarrays. Further analyses demonstrated that 65.38% (136/208) presented with low 5‑hmC level, and low 5‑hmC level was significantly associated with lymph node metastasis (P<0.001), histological type (P<0.001) and large tumor size (P=0.031). Notably, the 5‑year overall survival rate of patients with low 5‑hmC levels were significantly lower than patients with high 5‑hmC levels (P<0.001). In addition, it was demonstrated that 5‑hmC level was identified as independent prognostic factor in patients' overall survival. In conclusion, downregulation of 5-hmC may serve as a useful biomarker for NSCLC prognosis evaluation.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Qiu X, Liang Y, Sellers RS, Perez-Soler R and Zou Y: Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects. PLoS One. 9:e1098742014. View Article : Google Scholar : PubMed/NCBI
3	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
4	Liutkevičiūtė Z, Kriukienė E, Ličytė J, Rudytė M, Urbanavičiūtė G and Klimašauskas S: Direct decarboxylation of 5-carboxylcytosine by DNA C5-methyltransferases. J Am Chem Soc. 136:5884–5887. 2014. View Article : Google Scholar : PubMed/NCBI
5	Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, et al: Mutation in TET2 in myeloid cancers. N Engl J Med. 360:2289–2301. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wu H, Wu X, Shen L and Zhang Y: Single-base resolution analysis of active DNA demethylation using methylase-assisted bisulfite sequencing. Nat Biotechnol. 32:1231–1240. 2014. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Córdoba-Cañero D, Qian W, Zhu X, Tang K, Zhang H, Ariza RR, Roldán-Arjona T and Zhu JK: An AP endonuclease functions in active DNA dimethylation and gene imprinting in Arabidopsis (corrected). PLoS Genet. 11:e10049052015. View Article : Google Scholar : PubMed/NCBI
8	Dong ZR, Zhang C, Cai JB, Zhang PF, Shi GM, Gao DM, Sun HC, Qiu SJ, Zhou J, Ke AW and Fan J: Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma. Tumour Biol. 36:2763–2771. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H and Koike K: Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 103:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, Guo J and Ge D: Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 81:259–265. 2013. View Article : Google Scholar : PubMed/NCBI
11	Sica GL and Gal AA: Lung cancer staging: Pathology issues. Semin Diagn Pathol. 29:116–126. 2012. View Article : Google Scholar : PubMed/NCBI
12	Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al: WHO Panel: The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, Wang XY, Devbhandari RP and Fan J: CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology. 140:1629–1641.e15. 2011. View Article : Google Scholar : PubMed/NCBI
14	Zhao GY, Ding JY, Lu CL, Lin ZW and Guo J: The overexpression of 14-3-3ζ and Hsp27 promotes non-small cell lung cancer progression. Cancer. 120:652–663. 2014. View Article : Google Scholar : PubMed/NCBI
15	Hattman S: The first recognized epigenetic signal: DNA glucosylation of T-even bacteriopages. Epigenetics. 4:150–151. 2009. View Article : Google Scholar : PubMed/NCBI
16	Yin R, Mo J, Lu M and Wang H: Detection of human urinary 5-hydroxymethylcytosine by stable isotope dilution HPLC-MS/MS analysis. Anal Chem. 87:1846–1852. 2015. View Article : Google Scholar : PubMed/NCBI
17	Yang Q, Wu K, Ji M, Jin W, He N, Shi B and Hou P: Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol. 9:1607–1616. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kriaucionis S and Heintz N: The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 324:929–930. 2009. View Article : Google Scholar : PubMed/NCBI
19	Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L and Rao A: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 324:930–935. 2009. View Article : Google Scholar : PubMed/NCBI
20	Moen EL, Mariani CJ, Zullow H, Jeff-Eke M, Litwin E, Nikitas JN and Godley LA: New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine. Immunol Rev. 263:36–49. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ye C and Li L: 5-hydroxymethylcytosine: A new insight into epigenetics in cancer. Cancer Biol Ther. 15:10–15. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ulas A, Turkoz FP, Silay K, Tokluoglu S, Avci N, Oksuzoglu B and Alkis N: A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One. 9:e1144712014. View Article : Google Scholar : PubMed/NCBI
23	Campobasso O, Andrion A, Mancuso M, De Simone M and Ribotta M: The postoperative survival in pulmonary carcinomas depending on the histological type and stage. Ann Osp Maria Vittoria Torino. 31:9–24. 1989.(In Italian). PubMed/NCBI